Silo Pharma Inc

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in merging traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Englewood Cliffs, NJ.

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

Context Therapeutics LLC

Hillstream Biopharma

Intelligent Bio Solutions Inc

Rent the Runway

Sonoma Pharmaceuticals

Spectrum Pharma

Penny Stocks With News Light Up The Scanners This Week This week

7 Top Penny Stocks To Watch With Big News This Week

ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of the Company's common stock. The Company may purchase common stock in the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had approximately 3,138,797 million shares of common stock outstanding as of November 10, 2022, as reported in its Quarterly Report for the period ended September 30, 2022.

Silo Pharma Announces Stock Repurchase Program

Parkinson's disease, bipolar disorder, and chronic pain targeted in study

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

180 Life Sciences 

Dermata Therapeutics

Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Essential Strategies for Penny Stocks Trading in 2023

Ardelyx

Digital Brands Group Inc

NeuroBo Pharmaceuticals Inc

Penny stocks to watch this week with news before 2023. The post Best Penny Stocks To Buy Before 2023?

Best Penny Stocks To Buy Before 2023? 4 To Watch Now

SPU-21 effective in controlling arthritis progression.

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) --   Silo Pharma, Inc. ( Nasdaq: SILO ) (“the Company”) , a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company's progress and potential for its portfolio of novel, IP-protected technologies and assets developed in collaboration with world-class medical research partners. The letter, in its entirety, is reprinted below.

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine

Initial data from study expected in first quarter 2023

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Deswell Industries

VAALCO Energy

Flexible Solutions

United Microelectronics

Although the concept of millionaire-maker stocks will always attract attention, at the moment, investors must realize the rules have changed. Fundamentally, the Federal Reserve remains committed to attacking the inflation crisis through hiking the benchmark interest rate.

7 Millionaire-Maker Stocks You Will Regret Not Buying This Year

ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine.

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

ENGLEWOOD CLIFFS, NJ, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D. M.B.A, Vice President of R&D, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. Silo Pharma is a sponsor of the three-day conference being held November 3-5, 2022, in Miami, Florida.

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Silo Pharma (NASDAQ: SILO ) stock is falling on Thursday despite the company releasing positive data from a pre-clinical study. This data covers the use of SPC-14 as a therapeutic treatment for Alzheimer's disease.

What Is Going on With Silo Pharma (SILO) Stock Today?

Dosing study of SPC-14 demonstrates efficacy for increasing memory function Dosing study of SPC-14 demonstrates efficacy for increasing memory function

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer's Disease in Pre-Clinical Study

Studies of SP-26, the company's proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Presentation to feature Company's novel therapeutic candidates under development in collaboration with leading academic institutions

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters' over-allotment option to purchase 150,000 additional shares of common stock, at a public offering price of $5.00 per share.

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter's Over-Allotment Option

In today's turbulent market, what was once green is now red for many companies across all major indices. That said, among today's bigger losers is Silo Pharma (NASDAQ: SILO ), as this early-stage biotech stock is set for its Nasdaq initial public offering (IPO).

Can Silo Pharma (SILO) Stock Be a Hot Nasdaq Debut?

Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO” Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO”

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

ENGLEWOOD CLIFFS, NJ , Sept. 15, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it will effect a 1-for-50 reverse split of its common stock in preparation for the planned listing of the Company's securities on The Nasdaq Capital Market (“Nasdaq”). The reverse stock split will become effective at the open of business on Thursday, September 15, 2022, and the Company's common stock will begin trading on the OTC Markets system on a split-adjusted basis under the temporary ticker symbol “SILOD” at that time. The fifth character “D” will remain appended to the Company's symbol for 20 business days or until the Company is listed on Nasdaq, whichever comes first, at which point the Company's trading symbol will revert back to “SILO.”

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc  . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method.

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes

Silo Pharma Expands License Agreement and Patent Portfolio

Study is examining effects of Psilocybin on Inflammatory Markers ENGLEWOOD CLIFFS, N.J., May 19, 2022 (GLOBE NEWSWIRE) --  Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it in conjunction with the University of California San Francisco (UCSF), researchers have successfully dosed patients suffering from Parkinson's disease. As part of this study, the researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson's.

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study

SPU-21 has shown Anti-arthritic activity for therapeutic use in preclinical studies. SPU-21 has shown Anti-arthritic activity for therapeutic use in preclinical studies.

News for Silo Pharma Inc Stock (SILO)